Candesartan (Atacand) given as prophylaxis reduced the severity and duration of migraine, according to the results of a randomized trial reported in the Jan. 1 issue of The Journal of the American Medical Association.
“The prophylactic agents available today have limited efficacy and may cause adverse effects not compatible with long-term use,” write Erling Tronvik, MD, from St. Olavs Hospital in Trondheim, Norway, and colleagues.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!